Delcath Systems, Inc. (NASDAQ:DCTH) Forecasted to Earn Q1 2025 Earnings of ($0.25) Per Share

Delcath Systems, Inc. (NASDAQ:DCTH) – Analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Delcath Systems in a report released on Wednesday, March 27th. HC Wainwright analyst S. Ramakanth forecasts that the company will post earnings per share of ($0.25) for the quarter. HC Wainwright currently has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Delcath Systems’ current full-year earnings is ($1.90) per share. HC Wainwright also issued estimates for Delcath Systems’ Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.16) EPS and FY2028 earnings at $1.76 EPS.

Delcath Systems (NASDAQ:DCTH) last posted its earnings results on Tuesday, March 26th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.19. The business had revenue of $0.54 million for the quarter, compared to analyst estimates of $0.48 million. Delcath Systems had a negative net margin of 2,308.86% and a negative return on equity of 563.60%. During the same quarter in the previous year, the business posted ($0.86) EPS.

Separately, StockNews.com upgraded shares of Delcath Systems to a “sell” rating in a report on Wednesday. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to MarketBeat, Delcath Systems has a consensus rating of “Moderate Buy” and a consensus target price of $18.50.

Delcath Systems Stock Performance

NASDAQ:DCTH opened at $4.77 on Friday. The firm’s fifty day simple moving average is $4.36 and its 200 day simple moving average is $3.85. Delcath Systems has a twelve month low of $2.25 and a twelve month high of $7.99.

Insider Buying and Selling

In other news, Director Gil Aharon purchased 26,882 shares of the company’s stock in a transaction that occurred on Tuesday, March 19th. The shares were purchased at an average price of $3.72 per share, with a total value of $100,001.04. Following the purchase, the director now directly owns 1,069,710 shares of the company’s stock, valued at approximately $3,979,321.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 21.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Delcath Systems

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC increased its stake in Delcath Systems by 107.8% during the 1st quarter. Tower Research Capital LLC TRC now owns 4,663 shares of the company’s stock worth $26,000 after buying an additional 2,419 shares during the period. Millennium Management LLC purchased a new stake in Delcath Systems during the 2nd quarter worth $40,000. GSA Capital Partners LLP bought a new stake in shares of Delcath Systems in the 3rd quarter worth about $63,000. Renaissance Technologies LLC bought a new stake in shares of Delcath Systems in the 1st quarter worth about $70,000. Finally, WealthPlan Investment Management LLC bought a new stake in shares of Delcath Systems in the 4th quarter worth about $73,000. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.